Letter to the Editor: From prediction to prevention: Integrating nomograms and pathogen biology in multidrug-resistant pyogenic liver abscess

Abstract

The increasing incidence of multidrug-resistant (MDR) Gram-negative pyogenic liver abscess (PLA) is reshaping diagnostic and therapeutic paradigms in hepatobiliary medicine. The study by Xu et al, published in the recent issue of the World Journal of Gastroenterology, developed a predictive nomogram incorporating five independent factors-advanced age, diabetes, malignancy, lower C-reactive protein levels, and prolonged prothrombin time-to estimate individualized MDR risk. This letter critically examines the methodological and clinical implications of that model, discussing how predictive analytics may evolve into preventive frameworks when combined with biological insight and stewardship integration. The proposed nomogram is a practical bedside instrument that operationalizes MDR risk estimation in clinical environments increasingly dominated by Klebsiella pneumoniae and Escherichia coli. Its discrimination is robust, though single-center derivation constrains external validity. Augmenting predictive accuracy through dynamic biomarkers-such as interleukin-6 and procalcitonin-could better capture host-response kinetics. Mechanistic evidence indicates that MDR strains’ enhanced virulence (biofilm formation, siderophore-mediated iron uptake, capsule hyperexpression) supports integrating pathogen biology into prediction. Embedding risk models within antimicrobial stewardship pathways may promote timely source control, rational empiric therapy, and structured de-escalation. Beyond statistical modeling, innovation lies in transforming prediction into prevention. Multicenter validation, genomic correlation, and digital recalibration will determine whether predictive tools can reduce MDR-PLA burden. Aligning data-driven analytics with infection biology and governance can shift hepatology from reactive treatment toward proactive resistance prevention.

Key Words: Critically ill patients; Pyogenic liver abscess; Multidrug-resistant Gram-negative bacteria; Predictive nomogram; Antimicrobial stewardship; Host-pathogen interaction

Core Tip: Xu et al proposed a bedside nomogram to estimate the probability of multidrug-resistant (MDR) Gram-negative pyogenic liver abscess (PLA) using five routinely available variables. This letter clarifies how such risk stratification can be operationalized at the bedside through concrete clinical scenarios, while arguing that prediction becomes clinically meaningful only when coupled to actionable pathways: Early imaging and source control, rapid resistance-gene testing where available, guideline-concordant empiric coverage in high-risk patients, and stewardship-driven de-escalation. Integrating host vulnerability with pathogen biology may allow hepatology services to move from delayed recognition to prevention-oriented management of MDR-PLA.

TO THE EDITOR

The rising prevalence of multidrug-resistant (MDR) Gram-negative pyogenic liver abscess (PLA) is increasingly challenging established therapeutic strategies in hepatobiliary care. In a single-center retrospective cohort study published in the recent issue of the World Journal of Gastroenterology by Xu et al[1] comprising 268 microbiologically confirmed cases, identified five variables independently associated with MDR infection-older age, diabetes mellitus, malignancy, reduced C-reactive protein (CRP) levels, and prolonged prothrombin time-and integrated them into a bedside nomogram for individualized risk estimation. This approach represents a step toward risk-adapted management in a clinical setting traditionally dominated by empiric, non-stratified antimicrobial therapy.

Shifting microbiological patterns and host vulnerability

During the past two decades, Klebsiella pneumoniae (K. pneumoniae) has progressively overtaken Escherichia coli as the predominant pathogen responsible for PLA, particularly across East Asian populations[2]. In contrast, European and North American cohorts continue to report heterogeneous and frequently polymicrobial etiologies[3]. Among host-related factors, diabetes mellitus consistently emerges as a major determinant of susceptibility, reflecting impaired neutrophil function, hepatic microvascular dysfunction, and cumulative healthcare exposure[4]. Similarly, malignancy and treatment-related immunosuppression increase vulnerability to complicated hepatobiliary infections, including invasive fungal liver involvement[5]. Within this framework, the inverse association between CRP concentrations and MDR pathogens observed by Xu et al[1] is biologically plausible. Rather than indicating a milder infectious process, lower inflammatory marker levels may signal blunted immune activation in frail or immunocompromised hosts, limiting the interpretability of conventional severity surrogates in this subgroup.

Beyond static predictors: Toward dynamic risk assessment

Although the nomogram demonstrates favorable discrimination, derivation from a single institutional dataset limits external applicability. Integrating dynamic biomarkers-such as interleukin-6 (IL-6) or procalcitonin-may refine risk stratification by capturing temporal host-response kinetics[6]. Meta-analytic evidence supports an association between IL-6 levels and sepsis mortality, suggesting potential translational value for risk modeling[6]. However, any gain in accuracy must be balanced against bedside usability, particularly in settings where rapid biomarker panels are not routinely accessible.

Pathophysiological insights and pathogen-specific considerations

MDR K. pneumoniae strains may co-express virulence traits-capsule hyperexpression, biofilm formation, and siderophore-mediated iron acquisition-that facilitate immune evasion and dissemination[7]. Conceptually, this supports a shift from purely “pathogen-named” prediction to integrated host-pathogen risk frameworks that combine vulnerability, inflammatory response, and microbiological ecology. Consistent with this view, MDR-associated PLA has been linked to worse clinical trajectories in contemporary cohorts[8,9].

Translating risk prediction into clinical management

Risk prediction becomes clinically valuable only if it changes early decisions. Patients classified as high risk by the nomogram should trigger expedited imaging, early source control, and empiric therapy aligned with local resistance patterns[1]. Observational evidence indicates that timely drainage combined with appropriate antimicrobial therapy reduces recurrence and mortality[3,8]. Crucially, predictive tools should be embedded into antimicrobial stewardship pathways-predefined de-escalation triggers, ongoing antibiogram review, and decision-support prompts-to reduce unnecessary exposure to last-line agents and preserve activity of novel compounds[10,11].

Clinical scenarios: Applying the nomogram in practice

To operationalize implementation, the following scenarios illustrate how nomogram-derived MDR probability could shape real-world bedside choices.

Scenario 1 - high predicted risk and early targeted coverage: A 68-year-old man with long-standing diabetes mellitus and recent biliary stent placement presents with fever and a large right-lobe hepatic abscess [white blood cell (WBC) count 22000/μL, CRP 180 mg/L]. Nomogram application indicates a high MDR probability[1]. Based on this, empiric therapy is initiated with an agent active against carbapenem-resistant Enterobacterales according to local epidemiology and specialist input. Rapid molecular testing on aspirate identifies blaKPC within 24 hours, supporting early targeted therapy and enabling prompt clinical improvement. This scenario highlights how high-risk stratification can justify immediate resistance-aware empiric therapy while avoiding a “third-generation cephalosporin first” delay.

Scenario 2 - intermediate risk and molecular-guided escalation: A 45-year-old woman receiving chemotherapy for colorectal cancer presents with fever and multiple small abscesses after recent hospitalization (WBC count 18000/μL, CRP 150 mg/L). Nomogram-derived MDR risk is intermediate[1]. Because intermediate estimates are clinically ambiguous, rapid resistance-gene testing is prioritized and detects blaNDM within hours. In line with contemporary guidance for metallo-β-lactamase producers, therapy is escalated to a regimen with activity against NDM (for example, cefiderocol, or ceftazidime-avibactam plus aztreonam where available), paired with source control planning and close monitoring[11]. The key implementation point is not “more antibiotics”, but earlier molecular triage that prevents delayed active therapy while still allowing de-escalation when results exclude high-risk mechanisms.

Scenario 3 - low predicted risk and stewardship-oriented management: A 32-year-old previously healthy man presents with community-acquired PLA (WBC count 12000/μL, CRP 90 mg/L) and no recognized MDR risk factors. The nomogram yields a low MDR probability[1]. Empiric ceftriaxone is started; cultures later grow fully susceptible K. pneumoniae[2]. The patient defervesces quickly and is discharged after clinical stabilization. Here, risk stratification supports narrow-spectrum empiric therapy and avoids unnecessary escalation-an immediate stewardship benefit.

Integrated decision-making and stewardship impact

Across these scenarios, the primary value of the nomogram lies in enabling consistent, protocolized first-day decisions. High-risk classification can justify early resistance-aware empiric therapy and expedited source control, whereas low-risk classification supports narrower empiric coverage with early de-escalation. When combined with rapid genotypic testing, the approach may reduce both delayed active therapy and avoidable exposure to broad-spectrum agents, aligning bedside decisions with stewardship governance[10,11].

Implementation challenges and future perspectives

For pragmatic adoption, the nomogram should be embedded into electronic health records or mobile decision-support platforms to auto-calculate MDR probability and prompt predefined actions: Early imaging, drainage referral, rapid molecular testing where available, and stewardship review. Prospective multicenter validation is needed, especially in regions where resistance mechanisms and virulence profiles differ substantially. Future iterations may incorporate evolving antibiograms, biomarker kinetics, and recalibration methods to preserve model performance over time.

Conclusion

The nomogram developed by Xu et al[1] is a meaningful step toward precision-oriented management of MDR-PLA. Its clinical relevance will depend on implementation: Coupling risk prediction to actionable pathways, integrating pathogen biology and rapid diagnostics, and embedding decisions within stewardship frameworks. If validated across settings, such tools can help shift hepatobiliary infection management from reactive escalation to prevention-oriented care in an increasingly resistant landscape.